$13.81
-0.14 (-1.00%)
Open$13.80
Previous Close$13.95
Day High$14.22
Day Low$13.65
52W High$22.88
52W Low$9.01
Volume—
Avg Volume136.6K
Market Cap182.58M
P/E Ratio—
EPS$-0.27
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+73.6% upside
Current
$13.81
$13.81
Target
$23.98
$23.98
$18.55
$23.98 avg
$27.85
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 104.02M | 115.94M | 23.45M |
| Net Income | -10,031,881 | -10,063,188 | 5.38M |
| Profit Margin | -9.6% | -9.2% | 22.9% |
| EBITDA | -5,236,726 | -5,544,906 | 8.65M |
| Free Cash Flow | — | — | 4.59M |
| Rev Growth | -10.3% | -10.3% | -4.1% |
| Debt/Equity | — | — | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |